Patented biomarker for cardiac injury. 

Patented biomarker for cardiac injury. 

Tag: AHF

Changes in levels of the novel biomarker cMyC were significantly associated with hs-cTnI plasma levels in patients with symptomatic chronic HFrEF during a structured 12-week exercise training program. Being more sensitive may indicate a role as a future marker of subclinical myocardial damage.
The study brings new evidence supporting the role of MyBP-C as a comprehensive biomarker in AHF. While NT-proBNP remains the gold standard biomarker in AHF, MyBPC has been shown to have an impressive diagnostic performance with high sensitivity and specificity, providing complementary information. MyBP-C may serve as a valuable adjunctive tool in enhancing diagnostic accuracy and guiding clinical decisions in AHF. In addition, MyBP-C has a promising role as a prognostic biomarker in AHF, being able to complement existing markers, and thus achieve better risk stratification and the prediction of short-term outcomes.
cMyC (Cardiac Myosin-Binding Protein C) may aid physicians in the rapid triage of patients with suspected Acute Heart Failure (AHF).
cMyC is mentioned in the 2020 ESC Guidelines for the management of acute coronary syndromes in NSTEMI patients as an alternative to troponin.